Type 2 diabetes combined with HFpEF
Conditions
Interventions
Exposure group:Taking Henagliflozin
Non-exposure group:Do not take Henagliflozin
Sponsors
Department of Cardiovascular Medicine, Hubei Third People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age>=18 years, =300 pg/ml (NT-pro BNP >=600 pg/ml for patients with atrial fibrillation); 3. Patients with confirmed chronic heart failure with preserved ejection fraction (LVEF>=50%); 4. Combined with type 2 diabetes mellitus, glycosylated hemoglobin (HbA1c) is between 7%-11%; 5. Cardiac Function Grading (NYHA) Class II-III; 6. Use of stable doses of guideline-recommended heart failure treatment drugs for at least 1 month prior to enrollment; 7. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of acute myocardial infarction, stroke or cardiac surgery within 6 months; 2. Severe valvular disease, pericardial disease or congenital heart disease; 3. Those who have been intolerant to other SGLT2 inhibitors in the past; 4. Use of SGLT2 inhibitors in the past 7 days; 5. Use of short-acting GLP-1RA in the past 7 days and long-acting GLP-1RA within 14 days; 6. Patients with active malignant tumors and unstable conditions, drug abuse or addiction; 7. In addition to the above, patients judged by the investigator to be unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular end-diastolic volume (LVEDV);Left ventricular end-systolic volume (LVESV); | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular end-diastolic volume (LVEDV);Left ventricular end-systolic volume (LVESV);Left ventricular mass index (LVMI); | — |
Countries
China
Contacts
Public ContactJingyi Zhang; Nianfang Luo
Department of Cardiovascular Medicine, Hubei Third People's Hospital
Outcome results
None listed